Enjoin Expands Executive Leadership Team with Key Appointment to Enhance Technology Strategy

New Role to Accelerate Growth with AI Footprint

NASHVILLE, Tenn., March 4, 2025 /PRNewswire/ -- Enjoin, a physician-directed leader in revenue integrity backed by the healthcare specialist private equity firm 3 Boomerang Capital, announced today the expansion of its executive leadership team to include Kaitlyn Labuda as the company's Executive Vice President of Product. This strategic hire will enhance its technology strategy and accelerate product development as Enjoin embarks on its next phase of growth.

Expanding upon Enjoin's platform-enabled services with predictive analytics, Kaitlyn will grow Enjoin's AI footprint leveraging decades of physician clinical and coding expertise for every patient discharge to drive continued documentation and revenue integrity. Kaitlyn's innovative and disciplined approach coupled with her industry experience aligns with Enjoin's commitment to documentation excellence.

Kaitlyn played a key role in launching and managing a cloud-based clinical documentation integrity (CDI) solution which earned a Best in KLAS CDI technology solution award. She holds a bachelor's degree in Health Information Management from the University of Pittsburgh.

"This new role reflects our commitment to strengthening our leadership team and positioning the company for accelerated growth as it builds upon its strong foundation in mid-revenue cycle," said Justin Schmidt, CEO of Enjoin. "As we continue to expand our capabilities and deliver exceptional value to our clients, Kaitlyn's expertise will be instrumental in driving our product strategies forward."

About Enjoin

For over 35 years. Enjoin has helped organizations fully tell their patients' stories, aligning physician-directed services to enhance mid-revenue cycle functions for better documentation and coding quality. Led by acclaimed physicians with extensive clinical practice experience, coupled with certified coding and clinical documentation credentials, our approach enhances clinical documentation with deep expertise, driving physician engagement, revenue integrity, reducing costs and mitigating risk. Clients achieve demonstrable enhancements to CMI, coding accuracy, quality metrics, risk adjustment and physician alignment for an average ROI of more than 700%. For more information, visit www.enjoincdi.com.

About 3 Boomerang Capital

3 Boomerang Capital is a lower middle-market healthcare private equity firm committed to fostering creative investment partnerships with healthcare entrepreneurs across North America and Western Europe. 3BC's areas of investment focus span four key healthcare sectors: Biopharma outsourcing, medical device and diagnostic manufacturing, information technology and tech-enabled services, and alternate site care. The firm specializes in backing founder-led businesses, providing the guidance and resources needed for successful growth and innovation in the healthcare market. By strategically concentrating on four core areas, 3 Boomerang Capital is well-equipped to deliver on its mission of empowering healthcare entrepreneurs and propelling healthcare businesses to new heights. The firm is currently investing out of its flagship fund, 3 Boomerang Capital I, LP, a $376 million investment vehicle. For more information, visit www.3boomerang.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/enjoin-expands-executive-leadership-team-with-key-appointment-to-enhance-technology-strategy-302391644.html

SOURCE Enjoin